This trial is active, not recruiting.

Condition clostridium difficile infection
Sponsor Barts & The London NHS Trust
Start date October 2011
End date August 2015
Trial size 100 participants
Trial identifier NCT02086916, 007512QM, Barts and The London Charity


Acquiring diarrhoea in hospital is a serious problem and most frequently occurs when susceptible patients receive antibiotics as part of their (often life-saving) care. The commonest cause is Clostridium difficile - a bacterium that normally lives in up to a third of us but causes no problems. Rates of infection had been falling with increased awareness and improved hygiene but they are starting to creep up again. Clostridium difficile can cause a range of disease from a short-lived mild diarrhoea to severe disease of the bowel with major effects on the whole body and even death.

This study aims to identify substances in the stool and in the blood to enable doctors to predict how severe that individual's disease will be. These tests can easily be performed. If they prove accurate in identifying the subsequent severity of the patient's illness due to Clostridium difficile, patients predicted to develop the worst disease can receive the most intensive treatments before they become too unwell to benefit. On the other hand, patients whose disease is predicted by these markers to run its course without causing serious consequences can be spared the side effects and risks of more intensive treatment.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Observational study, hence no intervention will be administered

Primary Outcomes

Failure of primary treatment
time frame: within 5 days

Secondary Outcomes

Death, CDI recurrence and hospital re-admission with diarrhoea
time frame: Within 3 months of the initial diagnosis of CDI

Eligibility Criteria

Male or female participants at least 16 years old.

Inclusion Criteria: - Test positive for CDI on stool analysis - Inpatient at Barts Health NHS Trust at time of diagnosis Exclusion Criteria: - Nil specific

Additional Information

Official title Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection
Principal investigator David S Rampton, DPhil, FRCP
Description Clostridium difficile infection (CDI), which is often a consequence of antibiotic therapy, is the most common and one of the most serious hospital-acquired illnesses. It causes a range of intestinal upset from mild diarrhoea to a life-threatening severe colitis. The incidence, recurrence and mortality rates of CDI have increased dramatically in recent years. Metronidazole is the recommended first-line antibiotic, with vancomycin and colectomy reserved for severe cases. Although risk factors for developing CDI are well known, factors that predict outcome and/or recurrence of CDI are uncertain and lack specificity for intestinal inflammation. We wish to investigate if careful prospective monitoring of standard clinical and biochemical measures will be able to identify patients who will go on to fail primary treatment. If one or more of these factors proves able to predict outcome, they could ultimately be used for early escalation of therapy with the aim of reducing morbidity, mortality and length of hospital stay.
Trial information was received from ClinicalTrials.gov and was last updated in July 2015.
Information provided to ClinicalTrials.gov by Barts & The London NHS Trust.